ReviewNature reviews. Rheumatology2013
The influence of ageing on the development and management of rheumatoid arthritis.
Review in Nature reviews. Rheumatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Article
- Insights into the therapeutic strategies for aging and aging-associated diseases.Signal transduction and targeted therapy · 2026Review
- Age-Dependent Differences in Canakinumab Safety: A Comprehensive Pharmacovigilance Analysis Using the FAERS Database.Pharmacology research & perspectives · 2026Article
- Intersecting Social Identities and Health in Arthritis: A Latent Class Analysis of the Canadian Longitudinal Study on Aging.ACR open rheumatology · 2026Article
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- Frailty in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: Current evidence and knowledge gaps.Therapeutic advances in musculoskeletal disease · 2026Review
- Outcomes of respiratory syncytial virus infection in patients with systemic autoimmune rheumatic disease.Seminars in arthritis and rheumatism · 2025Article
- Late Onset Rheumatoid Arthritis.Aging and disease · 2025Review
- A Longitudinal Study Reveals Metabolomic Markers for Individuals at Risk, Disease Severity, and Treatment Response in Rheumatoid Arthritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Ageism in Rheumatology: The Health Care Professional's Perspective.Arthritis care & research · 2025Article
- Epigenetic age acceleration and rheumatoid arthritis: an NHANES-based analysis and survival prediction models.Clinical epigenetics · 2025Article
- Article
- Managing Rheumatoid Arthritis in Older Adults with Cancer.Drugs & aging · 2025Review
- Genomic Locus Tagged by Lung Function GWAS SNV rs12477314 (2q37.3) Acts as a Regulatory Region for a Systemic Inflammatory Phenotype.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Medication Adherence and Illness Perception in Patients with Rheumatoid Arthritis: The Mediating Effect of Self-Efficacy.Journal of musculoskeletal & neuronal interactions · 2025Article
- The relationship between biological aging and psoriasis: evidence from three observational studies.Immunity & ageing : I & A · 2025Article
- CX3CR1Inflammation and regeneration · 2025Article
- Senolytic treatment to rescue hallmarks of senescence in lymph node fibroblasts from patients with rheumatoid arthritis: Implications for premature aging and potential therapeutic intervention in early rheumatoid arthritis.Clinical and experimental immunology · 2025Article
- Healthy and premature aging of monocytes and macrophages.Frontiers in immunology · 2025Review
- Musculoskeletal Organs-on-Chips: An Emerging Platform for Studying the Nanotechnology-Biology Interface.Advanced materials (Deerfield Beach, Fla.) · 2025Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The population of elderly individuals with rheumatoid arthritis (RA) is expanding, due mainly to increasing life expectancy. A variety of theories have been proposed to explain the ageing process, including accumulation of DNA damage and resultant changes in biological processes. Such changes can influence the development and/or course of disease. Furthermore, alterations in biological function determine the biological age-as opposed to chronological age-of an individual, which strongly influences their ability to cope with disease. Moreover, comorbidities are more frequent in elderly individuals. Together, these factors complicate treatment of disease and necessitate careful patient management. Indeed, although evidence from clinical trials suggests that DMARDs and biologic agents have good efficacy and are well tolerated in elderly patients with RA, such individuals are often undertreated and inadequately managed. Unfortunately, insufficient data are available for the development of evidence-based guidelines for this population, as elderly patients are often excluded from clinical trials owing to age restrictions or comorbidities. Thus, additional clinical studies in elderly patients are warranted, with treatment regimens tailored according to vitality or frailty parameters. This Review focuses on the pathophysiological aspects of ageing and their implications for the management of RA in elderly patients.
Indexed as
Identifiers
23774902What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.